The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Jeong Heo
No relevant relationships to disclose
Caroline Breitbach
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Mong Cho
No relevant relationships to disclose
Tae-Ho Hwang
Consultant or Advisory Role - Jennerex Biotherapeutics (U)
Stock Ownership - Jennerex Biotherapeutics
Research Funding - Jennerex Biotherapeutics
Chang Won Kim
No relevant relationships to disclose
Ung Bae Jeon
No relevant relationships to disclose
Hyun Young Woo
No relevant relationships to disclose
Ki Tae Yoon
No relevant relationships to disclose
Jun Woo Lee
No relevant relationships to disclose
James Burke
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Theresa Hickman
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Lara Longpre
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Richard H. Patt
Consultant or Advisory Role - Jennerex Biotherapeutics
David H. Kirn
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics